Health & Environmental Research Online (HERO)


Print Feedback Export to File
4101702 
Journal Article 
The association of Crk-like adapter protein with poor prognosis in glioma patients 
Yao, C; Lv, S; Han, M; Zhang, J; Zhang, Y; Zhang, L; Yi, R; Zhuang, D; Wu, J 
2014 
1 
Tumor Biology
ISSN: 1010-4283
EISSN: 1423-0380 
35 
6 
5695-5700 
English 
24563280 
WOS:000337094900082 
has retraction 4098513 Retraction Note to multiple articles in Tumor Biology
Glioma is the most common of brain tumors that greatly affects patient survival. In our precious study, Crk-like adapter protein (CrkL) was identified as a key regulator in glioblastoma development [1]. Here, we aimed to investigate the correlation of CrkL with patient prognosis as well as pathological indicators. Immunohistochemistry was available to evaluate CrkL expression in 49 gliomas of distinct malignancy grade, and positive stained sites were analyzed. CrkL protein was detected in cell lines by Western blot as well. We observed CrkL protein stained in 59.2 % (29 out of 49) of all glioma tissues, including 41.4 % of low-grade (I + II) gliomas, and 85.0 % of high-grade (III + IV) gliomas. Of four grades, grade IV exhibited the highest CrkL level. CrkL protein was also identified in cell lines NHA, U87, U251, T98G, and A172 by Western blot. On the other hand, CrkL expression was significantly associated with the patient's age and WHO grade, and patients with high CrkL expression had a significantly shorter median survival time (17 months) than those (median survival time 52 months) with low CrkL expression (p<0.001). According to Cox regression, CrkL can be suggested as an independent prognostic factor. In conclusion, CrkL is differently expressed in different grades of gliomas, and correlated to WHO grade. CrkL also independently indicates poor prognosis in old glioma patients, which can further be recommended as an effective prognostic biomarker or therapeutic target.